Outcomes of Middle Eastern Patients Undergoing Percutaneous Coronary Intervention: The Primary Analysis of the First Jordanian PCI Registry
- PMID: 28584584
- PMCID: PMC5448249
- DOI: 10.4103/1995-705X.206206
Outcomes of Middle Eastern Patients Undergoing Percutaneous Coronary Intervention: The Primary Analysis of the First Jordanian PCI Registry
Abstract
Aim: This is a prospective multicenter registry designed to evaluate the incidence of adverse cardiovascular events in Middle Eastern patients undergoing percutaneous coronary interventions (PCI). The registry was also designed to determine the predictors of poor outcomes in such patients.
Methods and results: We enrolled 2426 consecutive patients who underwent PCI at 12 tertiary care centers in Jordan between January 2013 and February 2014. A case report form was used to record data prospectively at hospital admission, discharge, and 12 months of follow-up. Mean age was 56 ± 11 years, females comprised 21% of the study patients, 62% had hypertension, 53% were diabetics, and 57% were cigarette smokers. Most patients (77%) underwent PCI for acute coronary syndrome. In-hospital and 1-year mortality rates were 0.78% and 1.94%, respectively. Definite or probable stent thrombosis occurred in 9 patients (0.37%) during hospitalization and in 47 (1.94%) at 1 year. Rates of target vessel repeat PCI and coronary artery bypass graft surgery at 1 year were 3.4% and 0.6%, respectively. The multivariate analysis revealed that cardiogenic shock, congestive heart failure, ST-segment deviation, diabetes, and major bleeding were significantly associated with higher risk of 1-year mortality.
Conclusions: In this first large Jordanian registry of Middle Eastern patients undergoing PCI, patients treated were relatively young age population with low in-hospital and 1-year adverse cardiovascular events. Certain clinical features were associated with worse outcomes and may warrant aggressive therapeutic strategies.
Keywords: Acute coronary syndrome; coronary artery disease; middle east; multicenter registry; percutaneous coronary intervention.
Conflict of interest statement
Dr. Ayman Hammoudeh is the recipient of the AstraZeneca grant.
References
-
- Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet. 2004;364:937–52. - PubMed
-
- Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347–60. - PubMed
-
- Hammoudeh AJ, Izraiq M, Hamdan H, Tarawneh H, Harassis A, Tabbalat R, et al. High-sensitivity C-reactive protein is an independent predictor of future cardiovascular events in Middle Eastern patients with acute coronary syndrome. CRP and prognosis in acute coronary syndrome. Int J Atheroscler. 2008;3:50–5.
-
- Saleh A, Hammoudeh AJ, Hamam I, Khader YS, Alhaddad I, Nammas A, et al. Prevalence and impact on prognosis of glucometabolic states in acute coronary syndrome in a Middle Eastern country: The GLucometabolic abnOrmalities in patients with acute coronaRY syndrome in Jordan (GLORY) study. Int J Diabetes Dev Ctries. 2012;32:37–43.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
